Epigenomics extends collaboration with Roche for screening products

By Lisa Kerner

Erie, Pa., March 22 - Epigenomics AG said it has extended its collaboration with Roche Diagnostics on blood screening products for various cancers until Sept. 30, 2007.

Under the extended collaboration, Epigenomics will be responsible for validating sensitivity for its improved blood screening tests for colorectal, prostate and breast cancer. The company will also expand its existing marker panels, optimize assays and validate them in patient studies.

Epigenomics will deliver results on marker panel performance studies and workflow adaptations until Oct. 15, 2006 for prostate cancer screening, and until March 30, 2007 for the breast cancer screening.

"The development of the colon cancer screening test has been very rewarding," Epigenomics chief executive officer Alexander Olek said in a company news release.

"We have gained significant knowledge in the development of this test that we will apply to the other screening tests and move them forward as fast as possible."

Berlin-based Epigenomics is a molecular diagnostic company focused on the development of novel products for cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.